Nothing Special   »   [go: up one dir, main page]

MX2010001218A - Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos. - Google Patents

Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.

Info

Publication number
MX2010001218A
MX2010001218A MX2010001218A MX2010001218A MX2010001218A MX 2010001218 A MX2010001218 A MX 2010001218A MX 2010001218 A MX2010001218 A MX 2010001218A MX 2010001218 A MX2010001218 A MX 2010001218A MX 2010001218 A MX2010001218 A MX 2010001218A
Authority
MX
Mexico
Prior art keywords
methods
compositions
combination therapy
treating schizophrenia
antipsychotic
Prior art date
Application number
MX2010001218A
Other languages
English (en)
Inventor
Sergey Olegovich Bachurin
Vladimir Viktorovich Grigoriev
Margarita A Morozova
Allan G Beniashvili
Original Assignee
Medivation Neurology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2007129568/15A external-priority patent/RU2508096C2/ru
Priority claimed from RU2007129567/15A external-priority patent/RU2508106C2/ru
Application filed by Medivation Neurology Inc filed Critical Medivation Neurology Inc
Publication of MX2010001218A publication Critical patent/MX2010001218A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invenci?n se relaciona con terapias combinadas y m?todo para el tratamiento, prevenci?n y/o retraso del inicio y/o el desarrollo de esquizofrenia, donde las terapias combinadas comprenden pirido (4,3-b) indol hodrogeando o una sal farmac?uticamente aceptable de lo mismo, como dimebon, y un agente antipsic?tico.
MX2010001218A 2007-08-01 2008-08-01 Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos. MX2010001218A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2007129568/15A RU2508096C2 (ru) 2007-08-01 2007-08-01 Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
RU2007129567/15A RU2508106C2 (ru) 2007-08-01 2007-08-01 Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
PCT/US2008/009357 WO2009017836A1 (en) 2007-08-01 2008-08-01 Methods and compositions for treating schizophrenia using antipsychotic combination therapy

Publications (1)

Publication Number Publication Date
MX2010001218A true MX2010001218A (es) 2010-04-07

Family

ID=40304696

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001218A MX2010001218A (es) 2007-08-01 2008-08-01 Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.

Country Status (10)

Country Link
US (1) US20110269777A1 (es)
EP (1) EP2175724A4 (es)
JP (1) JP2010535220A (es)
KR (1) KR20100054812A (es)
CN (1) CN101842010A (es)
AU (1) AU2008282742A1 (es)
BR (1) BRPI0815850A2 (es)
CA (1) CA2719824A1 (es)
MX (1) MX2010001218A (es)
WO (1) WO2009017836A1 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7837812B2 (en) 2004-05-21 2010-11-23 Ati Properties, Inc. Metastable beta-titanium alloys and methods of processing the same by direct aging
WO2009038764A1 (en) 2007-09-20 2009-03-26 D2E, Llc Fluoro-containing derivatives of hydrogented pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
RU2544856C2 (ru) 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
PE20091820A1 (es) 2008-03-24 2009-12-10 Medivation Technologies Inc Compuestos heterociclicos con uniones puente y metodos para usarlos
CA2719412A1 (en) 2008-03-24 2009-10-01 Medivation Technologies, Inc. Pyrido[3,4-b]indoles and methods of use
KR102317698B1 (ko) 2008-05-27 2021-10-25 인트라-셀룰라 써래피스, 인코퍼레이티드. 수면 장애 및 다른 장애를 치료하기 위한 방법 및 조성물
EP2346332A4 (en) 2008-10-31 2012-08-08 Medivation Technologies Inc PYRIDOÝ4,3-BINDOLES CONTAINING RIGID FRAGMENTS
EP2348847A4 (en) 2008-10-31 2012-05-23 Medivation Technologies Inc AZEPINO [4, 5-B] INDOLE AND USE PROCESS
RU2011137419A (ru) 2009-02-11 2013-03-20 Суновион Фармасьютикалз Инк. Обратные агонисты и антагонисты гистамина н3 и способы их применения
US9149467B2 (en) 2009-04-10 2015-10-06 Institute Of Pharmacology And Toxicology Academy Of Military Medical Science P.L.A. China Sustained-release composition containing tetrahydropyrido[4,3-b]indole derivatives and preparation of the derivatives
AU2010242910B2 (en) * 2009-04-29 2015-11-12 Medivation Technologies, Inc. Pyrido [4,3-b] indoles and methods of use
JP5827943B2 (ja) 2009-04-29 2015-12-02 メディベイション テクノロジーズ, インコーポレイテッド ピリド[4,3−b]インドールおよびその使用方法
AU2010298168B2 (en) 2009-09-23 2015-11-19 Medivation Technologies, Inc. Pyrido(3,4-b)indoles and methods of use
AU2010298169B2 (en) 2009-09-23 2015-10-29 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
EP2480078A4 (en) 2009-09-23 2013-03-06 Medivation Technologies Inc PYRIDO- [4,3-B] INDOLE AND USE METHOD THEREFOR
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103433A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011103448A1 (en) * 2010-02-19 2011-08-25 Medivation Technologies, Inc. Methods and compositions for treating psychotic disorders using antipsychotic combination therapy
US9187471B2 (en) 2010-02-19 2015-11-17 Medivation Technologies, Inc. Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
JP6138491B2 (ja) 2010-02-24 2017-05-31 ザ ブロード インスティテュート, インコーポレイテッド 感染性疾患の病原体およびそれらの薬剤感受性を診断する方法
US9434747B2 (en) 2011-02-18 2016-09-06 Medivation Technologies, Inc. Methods of treating diabetes
AU2012219251B2 (en) 2011-02-18 2016-05-12 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
WO2012112963A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
US9035056B2 (en) 2011-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
US20150224120A1 (en) * 2011-09-14 2015-08-13 Catherine Clelland Compositions and methods for treating hyperprolinemia-associated mental disorders
WO2013119800A1 (en) 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
MX2014012374A (es) 2012-04-14 2015-04-17 Intra Cellular Therapies Inc Compuestos organicos.
WO2014128882A1 (ja) * 2013-02-21 2014-08-28 医療法人 和楽会 不安うつ病の治療薬
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
ES2846823T3 (es) 2013-03-15 2021-07-29 Intra Cellular Therapies Inc Compuestos orgánicos
WO2015085004A1 (en) 2013-12-03 2015-06-11 Intra-Cellular Therapies, Inc. Novel methods
CN111689966A (zh) 2014-04-04 2020-09-22 细胞内治疗公司 有机化合物
KR101646962B1 (ko) 2014-09-29 2016-08-10 한국과학기술연구원 CaM 저해활성을 가지는 페노싸이아진 유도체
WO2016109679A1 (en) * 2014-12-31 2016-07-07 Markovitz M D Ph D Paul Method of treating schizophrenia
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
WO2016205631A1 (en) * 2015-06-17 2016-12-22 Massachusetts Institute Of Technology Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders
EP3407888B1 (en) 2016-01-26 2020-12-30 Intra-Cellular Therapies, Inc. Pyridopyrroloquinoxaline compounds, their compositions and uses
DK3407889T3 (da) 2016-03-25 2021-08-09 Intra Cellular Therapies Inc Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet
US10654854B2 (en) 2016-03-28 2020-05-19 Intra-Cellular Therapies, Inc. Salts and crystals of ITI-007
WO2017172811A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel co-crystals
WO2017172795A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
US11331316B2 (en) * 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
KR102614709B1 (ko) 2016-12-20 2023-12-18 에르테에스 로만 테라피-시스테메 아게 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
EP3562484B1 (en) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
US11839604B2 (en) 2016-12-31 2023-12-12 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
RU2767410C2 (ru) 2017-03-24 2022-03-17 Интра-Селлулар Терапиз, Инк. Новые композиции и способы
US10035795B1 (en) 2017-04-06 2018-07-31 Korea Institute Of Science And Technology Phenothiazine derivatives having CaM inhibitory activity
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
CA3071119A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment or prophylaxis of central nervous system disorders
KR102667268B1 (ko) 2017-07-26 2024-05-17 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2019067591A1 (en) 2017-09-26 2019-04-04 Intra-Cellular Therapies, Inc. NEW SALTS AND CRYSTALS
CN111818911B (zh) * 2017-12-26 2022-11-18 广东东阳光药业有限公司 一种鲁拉西酮固体分散体及其制备方法
CA3094204A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
MX2020013335A (es) 2018-06-08 2021-05-27 Intra Cellular Therapies Inc Metodos novedosos.
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
SG11202012772XA (en) 2018-06-27 2021-01-28 Bioxcel Therapeutics Inc Film formulations containing dexmedetomidine and methods of producing them
CN112584837A (zh) 2018-08-31 2021-03-30 细胞内治疗公司 新方法
MX2021002321A (es) 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Nuevos metodos.
EP4134101A1 (en) 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuterated lumateperone for the treatment of the bipolar ii disorder
KR20220049526A (ko) 2019-07-19 2022-04-21 바이오엑셀 테라퓨틱스 인코포레이티드 비-진정성 덱스메데토미딘 치료 양생법
WO2021119334A1 (en) 2019-12-11 2021-06-17 Intra-Cellular Therapies, Inc. Organic compound
CN117412747A (zh) * 2021-02-26 2024-01-16 比奥克斯塞尔医疗股份有限公司 用于治疗激越的方法和组合物
CN115290775A (zh) * 2022-07-25 2022-11-04 上海市徐汇区中心医院 一种精神类药物质控品、其试剂盒、制备方法及应用
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS229067B1 (en) * 1981-08-20 1984-04-16 Svorad Stolc Medicinal preparation with antiarhythmic and supporting effect applied with hypoxia,and method of preparing active substance thereof
US4672117A (en) * 1985-09-16 1987-06-09 American Home Products Corporation Antipsychotic gamma-carbolines
US5300645A (en) * 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
US5631265A (en) * 1994-03-11 1997-05-20 Eli Lilly And Company 8-substituted tetrahydro-beta-carbolines
RU2140417C1 (ru) * 1995-10-17 1999-10-27 Институт физиологически активных веществ РАН Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения
TW470745B (en) * 1996-05-23 2002-01-01 Janssen Pharmaceutica Nv Hexahydro-pyrido[4,3-b]indole derivatives
BR0211608A (pt) * 2001-08-08 2006-04-04 Upjohn Co 1h-pirido[4,3-b]indóis terapêuticos
WO2005120463A1 (en) * 2004-06-09 2005-12-22 Ranbaxy Laboratories Limited Rapidly disintegrating tablets of risperidone
US20070117834A1 (en) * 2005-10-04 2007-05-24 David Hung Methods and compositions for treating Huntington's disease
CA2625210A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
RU2338537C2 (ru) * 2006-01-25 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
JP2010528016A (ja) * 2007-05-25 2010-08-19 メディベーション ニューロロジー, インコーポレイテッド 細胞を刺激するための方法および組成物

Also Published As

Publication number Publication date
EP2175724A4 (en) 2010-09-15
CA2719824A1 (en) 2009-02-05
AU2008282742A1 (en) 2009-02-05
CN101842010A (zh) 2010-09-22
KR20100054812A (ko) 2010-05-25
JP2010535220A (ja) 2010-11-18
BRPI0815850A2 (pt) 2014-10-07
EP2175724A1 (en) 2010-04-21
WO2009017836A1 (en) 2009-02-05
US20110269777A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
MX2010001218A (es) Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.
MX2009004516A (es) Metodos y terapias de combinacion para tratar enfermedad de alzheimer.
UA100400C2 (uk) Похідні спіроциклічних амідів
WO2011103460A8 (en) Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011019417A8 (en) Pyrido [4, 3-b] indoles and methods of use
WO2009094668A8 (en) New 2,3,4,5-tetrahydro-1h-pyrido[ 4,3-b] indole compounds and methods of use thereof
WO2010127177A8 (en) Pyrido [4,3-b] indoles and methods of use
UA99459C2 (en) 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
WO2008036410A3 (en) Methods and compositions for treating amyotrophic lateral sclerosis (als)
NZ703111A (en) Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
TW200740803A (en) Heterocyclic derivatives as modulators of ion channels
CA2603830A1 (en) PYRIDINE [2,3-B] PYRAZINONES
MY148583A (en) Pyridine [3,4-b] pyrazinones
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
HK1150597A1 (es)
MX2012004157A (es) 8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc.
MY158257A (en) Forms of rifaximin and uses thereof
MX2020008616A (es) Rocio de fentanilo sublingual.
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
MX2009012788A (es) Metodos y composiciones para estimular celulas.
ZA200710332B (en) Bicyclic derivatives as modulators of ion channels
SG170033A1 (en) Octahydro-pyrrolo[3,4-b] pyrrole derivatives and their use as histamine-3 receptor ligands
UA107952C2 (uk) ПОХІДНІ ІМІДАЗО[1,2-a]ПІРАЗИНУ І ЇХ ЗАСТОСУВАННЯ ДЛЯ ПРОФІЛАКТИКИ АБО ЛІКУВАННЯ НЕВРОЛОГІЧНИХ, ПСИХІАТРИЧНИХ І МЕТАБОЛІЧНИХ РОЗЛАДІВ І ЗАХВОРЮВАНЬ
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal